Verdence Capital Advisors LLC Purchases 453 Shares of Cencora, Inc. (NYSE:COR)

Verdence Capital Advisors LLC increased its position in shares of Cencora, Inc. (NYSE:COR) by 1.6% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 28,636 shares of the company’s stock after buying an additional 453 shares during the period. Verdence Capital Advisors LLC’s holdings in Cencora were worth $6,434,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the company. Proficio Capital Partners LLC bought a new position in Cencora during the fourth quarter worth $31,936,000. M&T Bank Corp raised its stake in Cencora by 4.3% during the fourth quarter. M&T Bank Corp now owns 15,592 shares of the company’s stock worth $3,503,000 after buying an additional 636 shares during the last quarter. Assetmark Inc. raised its stake in Cencora by 1,165.7% during the fourth quarter. Assetmark Inc. now owns 32,097 shares of the company’s stock worth $7,212,000 after buying an additional 29,561 shares during the last quarter. Triad Wealth Partners LLC bought a new position in Cencora during the fourth quarter worth $463,000. Finally, Cypress Capital Group raised its stake in Cencora by 0.4% during the fourth quarter. Cypress Capital Group now owns 20,356 shares of the company’s stock worth $4,574,000 after buying an additional 87 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Cencora Trading Down 0.8 %

NYSE:COR opened at $253.35 on Wednesday. Cencora, Inc. has a one year low of $214.77 and a one year high of $262.26. The company has a market cap of $49.13 billion, a PE ratio of 36.04, a PEG ratio of 1.31 and a beta of 0.49. The firm has a 50-day moving average of $242.78 and a 200-day moving average of $238.09. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.87%. The ex-dividend date of this dividend was Friday, February 14th. Cencora’s dividend payout ratio (DPR) is presently 31.29%.

Analyst Ratings Changes

Several research firms have weighed in on COR. Evercore ISI lifted their price target on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Wells Fargo & Company lifted their price target on shares of Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 29th. Mizuho began coverage on shares of Cencora in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price target for the company. UBS Group lifted their price target on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average target price of $277.90.

Insider Buying and Selling

In other Cencora news, EVP Silvana Battaglia sold 5,000 shares of the business’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the transaction, the executive vice president now directly owns 15,374 shares in the company, valued at $3,724,197.76. The trade was a 24.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert P. Mauch sold 4,970 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the completion of the transaction, the chief executive officer now owns 51,070 shares in the company, valued at approximately $13,022,850. The trade was a 8.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 11,648 shares of company stock worth $2,862,342. 10.80% of the stock is owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.